The Nature and Nurturing of Hybrid Academic-Community Cancer Centers
Abstract
With the increasing need for high-quality, state-of-the-art cancer care reaching more people than can be accommodated by National Cancer...
Drug-detached Naked Antibody Impairs ADC Efficacy
Abstract
Armed with cytotoxic payloads, antibody-drug conjugate (ADC) becomes able to kill its naked-antibody-resistant tumor cell. When ADC circulates in...
Registration of Antibody Drug Conjugates
Abstract
Antibody Drug Conjugates (ADC) are a rapidly expanding area of pharma company pipelines. They combine the targeting of...
Environmental Risk Assessment and New Drug Development
1.0 Abstract
In our globalized world, human pharmaceutical residues and traces of other (chemical) down-the-drain contaminants have become an environmental...
Antibody Drug Conjugate Development: Keys to Rapid IND Submission and Approval
Antibody drug conjugates (ADCs) are a relatively new type of drug that combines the targeting ability of a biologic...
Challenges in Environmental Testing of Multi-component Substances
1.0 Abstract
An Environmental Risk Assessment or ERA needs to clearly identify hazard and exposure to evaluate risk. Having good...
Trial of High Efficiency TFF Capsule Prototype for ADC Purification
Antibody-drug conjugates (ADCs) are an emerging class of highly targeted cancer therapies in which a monoclonal antibody is chemically...
Antibody-Drug Conjugates: Manufacturing Challenges and Trends
Antibody-drug conjugates (ADCs), a form of Immuno-conjugate or bio-conjugate, are an emerging class of medicines designed for high-specificity targeting...
Drugs and Drug Hunters
All products of the creative process are a reflection of the individual makeup of the inventors. A painting by...
To Reimburse or not to Reimburse – That is the Question
Novel, innovative (bio)pharmaceutical drugs are an important part of our global healthcare system, offering advanced, radical new personalized and...
